BioMarin gets FDA decision date for hemophilia gene therapy, but questions on review remain

The Food and Drug Administration accepted BioMarin Pharmaceutical’s latest approval application for a gene therapy designed to treat severe hemophilia A, and has set a target decision date of March 31.